Clinical Trial RESULTS
Clinical Trial
RESULTS
Research Sponsor: AstraZeneca AB
Drug Studied: Ticagrelor
National Clinical Trial #: NCT02482298
Eudra Clinical Trial #: 2014-005420-10
Protocol #: D5136C00008
Study Date: July 2015 to November 2016
Short Study Title: A study to learn if ticagrelor reduces the number of days
with pain in adult patients with sickle cell disease
Thank you!
As a clinical study participant, you belong to a large community of participants around
the world. You help researchers answer important health questions and discover new
medical treatments.
Thank you for taking part in the clinical study for the drug ticagrelor. This drug is being
developed to treat patients with a blood disease called sickle cell disease. You and all the
other participants helped researchers learn if ticagrelor helps reduce the number of days
with pain in patients with sickle cell disease.
AstraZeneca AB, the sponsor of this study, thanks you for your help and thinks it
is important for you to know the results of the study. An independent non-profit
organization called CISCRP prepared this summary of the study results for you with the
help of a medical writing organization. We hope it helps you understand and feel proud
of your important role in medical research. If you have questions about the results,
please speak with the doctor or staff at your study site.
Whatâ€™s happened since my study ended?
Your study started in July 2015 and ended in November 2016. The study included 87
participants at 18 study sites in Egypt, Italy, Kenya, Lebanon, Turkey, the United Kingdom,
and the United States. The table on the next page shows the number of participants
in each country.
1